Source:http://linkedlifedata.com/resource/pubmed/id/21501569
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2011-6-23
|
pubmed:abstractText |
The purpose of this study was to noninvasively monitor the therapeutic efficacy of cyclophosphamide (CTX) in a mouse model by dual-modality molecular imaging: positron emission tomography (PET) and bioluminescence imaging (BLI). Firefly luciferase (fLuc) transfected HCC-LM3-fLuc human hepatocellular carcinoma cells were injected subcutaneously into BALB/c nude mice to establish the experimental tumor model. Two groups of HCC-LM3-fLuc tumor-bearing mice (n ?=? 7 per group) were treated with saline or CTX (100 mg/kg on days 0, 2, 5, and 7). BLI and (18)F-fluorodeoxyglucose ((18)F-FDG) PET scans were done to evaluate the treatment efficacy. CTX induced a 25.25 ± 13.13% and 35.91 ± 25.85% tumor growth inhibition rate on days 9 and 12 posttreatment, respectively, as determined by BLI. A good linear correlation was found between the tumor sizes measured by caliper and the BLI signals determined by optical imaging (R(2) ?=? .9216). (18)F-FDG imaging revealed a significant uptake reduction in the tumors of the CTX-treated group compared to that in the saline control group (5.30 ± 1.97 vs 3.00 ± 2.11% ID/g) on day 16 after CTX treatment. Dual-modality molecular imaging using BLI and small-animal PET can play important roles in the process of chemotherapy and will provide noninvasive and reliable monitoring of the therapeutic response.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorodeoxyglucose F18,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1536-0121
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
278-83
|
pubmed:meshHeading |
pubmed-meshheading:21501569-Animals,
pubmed-meshheading:21501569-Antineoplastic Agents, Alkylating,
pubmed-meshheading:21501569-Cell Line, Tumor,
pubmed-meshheading:21501569-Cyclophosphamide,
pubmed-meshheading:21501569-Fluorodeoxyglucose F18,
pubmed-meshheading:21501569-Humans,
pubmed-meshheading:21501569-Luminescence,
pubmed-meshheading:21501569-Mice,
pubmed-meshheading:21501569-Mice, Inbred BALB C,
pubmed-meshheading:21501569-Mice, Nude,
pubmed-meshheading:21501569-Neoplasm Transplantation,
pubmed-meshheading:21501569-Neoplasms,
pubmed-meshheading:21501569-Positron-Emission Tomography,
pubmed-meshheading:21501569-Radiopharmaceuticals,
pubmed-meshheading:21501569-Random Allocation,
pubmed-meshheading:21501569-Treatment Outcome
|
pubmed:year |
2011
|
pubmed:articleTitle |
Dual-modality monitoring of tumor response to cyclophosphamide therapy in mice with bioluminescence imaging and small-animal positron emission tomography.
|
pubmed:affiliation |
Medical Image Processing Group, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
|
pubmed:publicationType |
Journal Article
|